Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials

Tokgozoglu L., Pirillo A., Catapano A. L.

EUROPEAN HEART JOURNAL, sa.27, ss.2377-2379, 2023 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Editöre Mektup
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1093/eurheartj/ehad485
  • Dergi Adı: EUROPEAN HEART JOURNAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.2377-2379
  • Hacettepe Üniversitesi Adresli: Evet

Özet

TG-lowering treatments and atherosclerotic CV disease risk. A TG-lowering approach that results in TG lowering with no effect on apoB levels provides no clinical benefit; indeed, CV risk reduction is achievable when TG-lowering is accompanied by a reduction in apoB levels. TG: triglyceride; CE: cholesteryl ester; apoB: apolipoprotein B; CV: cardiovascular.